Petosemtamab is a monoclonal antibody commercialized by Merus, with a leading Phase II program in Esophageal Squamous Cell Carcinoma (ESCC). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Petosemtamab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Petosemtamab is expected to reach an annual total of $283 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Petosemtamab (MCLA-158) is under development for the treatment of metastatic colorectal cancer and other solid tumors including cervical cancer, vaginal cancer, vulvar cancer, penile cancer, anal cancer, non-small cell lung cancer, squamous non-small cell lung cancer, gastric cancer, adenocarcinoma of the gastroesophageal junction, endometrial cancer, pancreatic cancer, salivary gland cancer, squamous esophageal cancer and head and neck squamous cell carcinoma. The therapeutic candidate is administered through intravenous route. It is a bi-specific monoclonal antibody which acts by targeting leucine rich repeat containing G protein-coupled receptor 5 (LGR5) and epidermal growth factor receptor (EGFR). The therapeutic candidate is developed based on ADCC-Biclonics technology platform.
Merus is a pharmaceutical company that discovers and develops antibody therapeutics for cancer indications. The company is investigating MCLA-128, for the treatment of metastatic breast cancer and solid tumors; ONO-4685, for the treatment of autoimmune disease. It is also evaluating MCLA-158 and MCLA-129, to treat solid tumors and MCLA-145, a T-cell agonist targeting hematological malignancy and solid tumors. Merus utilizes Multiclonics, Biclonics and Triclonics technology platform for developing antibodies to treat cancer. The company works in collaboration with Incyte Corporation, Simcere Pharmaceutical Group, Ono Pharmaceutical Co., Ltd. and Betta Pharmaceuticals Co Ltd to advance its pipeline products. Merus is headquartered in Utrecht, the Netherlands.
The company reported revenues of (US Dollars) US$49.1 million for the fiscal year ended December 2021 (FY2021), an increase of 64% over FY2020. The operating loss of the company was US$90 million in FY2021, compared to an operating loss of US$75.9 million in FY2020. The net loss of the company was US$66.8 million in FY2021, compared to a net loss of US$85.5 million in FY2020. The company reported revenues of US$6.6 million for the third quarter ended September 2022, a decrease of 48.1% over the previous quarter.
For a complete picture of Petosemtamab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.